Image

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Description

PRIMARY OBJECTIVES:

I. To develop a cohort (biobank of biospecimens and data) of subjects without pancreatic cancer who are at highrisk for pancreatic cancer due to: a strong family history, a mutation in a known pancreatic cancer predisposition gene, or fukuoka worrisome or high-risk pancreatic cysts.

II. To follow the cohort subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes.

III. To make biospecimen available to PCDC-approved projects to validate potential biomarkers for performance using nested case-control prospective designs.

OUTLINE: This is an observational study.

Participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.

Eligibility

Inclusion Criteria:

  • PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
    • Age: 50 or older, plus at least one of the following:
      • Mutation unknown or absent:
        • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
        • OR 2+ affected first degree relatives (FDR), defined as blood related parents, siblings, or children)
      • Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the
        following
        • CDKN2A/p16, PJS (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
      • OR 1+FDR or second degree relative (SDR) with PDAC and a known P/LP

        mutation in one or more of:

        • ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53

HIGH-RISK OR WORRISOME PANCREATIC CYSTS:

  • 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
    • High risk stigmata:
      • Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
      • Enhancing mural nodule ≥ 5 mm
      • Main pancreatic duct ≥ 10 mm
    • Worrisome features:
      • Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct => 6 mm
      • Cyst ≥ 3 cm
      • Enhancing mural nodule < 5 mm
      • Thickened/Enhancing cyst wall
      • Main duct size 5-9 mm
      • Pancreatitis
      • Lymphadenopathy
      • Increased CA 19-9
      • Cyst growth rate ≥ 5 mm /2 years

Exclusion Criteria:

  • * Is unable to provide informed consent
    • Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
    • Current or prior history of PDAC or total pancreatectomy
    • Is currently a prison inmate
    • Is not able to speak or read English

Study details
    Pancreatic Carcinoma

NCT06271291

Mayo Clinic

1 November 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.